GlobeNewswire

Cisco Releases New Developer Capabilities Across Its Intent-Based Networking Platform

Dela

ORLANDO, Fla., June 12, 2018 (GLOBE NEWSWIRE) -- CISCO LIVE - Cisco today announced that it has released new developer capabilities across its intent-based networking platform. These advancements underscore Cisco's continued progress in delivering an open, programmable platform that spans the entire network, from campus to data center, branch to edge. By providing an open network, Cisco is empowering 500,000 developers, 60,000 partners and three million network engineers to innovate upon the platform.

Intent-based networking represents a fundamental shift in the way networks are built and managed. Moving away from the manual, time-intensive methods by which networks are traditionally managed, these modern networks capture business intent and translate it into network policies. These policies are then automatically activated across the entire infrastructure, with the assurance that the business intent was delivered as planned.

"Intent-based networking represents the next generation of open, IP-based systems that we've seen can change the actual fabric of society," said David Goeckeler, executive vice president and general manager of Cisco's Networking and Security Business. "Cisco is building an open architecture that will power an ecosystem to accelerate intent-based networking innovation. Already, our customers and partners are creating value from their networks in ways they thought weren't possible as recently as one year ago."

Announcing the DNA Center platform 
Today, Cisco is releasing new developer tools and open APIs into Cisco DNA(TM) Center - the command and control center for campus, branch and edge intent-based networks. DNA Center turns the network from a combination of hardware devices into a single system. With the availability of network-wide APIs, Cisco now allows developers to easily program this system, tapping into all of the analytics and insight the network can provide.

With a rich API catalog, DNA Center allows customers to protect and inform their business like never before.

Elevating network intelligence into business operations: DNA Center helps enable developers to program the network as a single system through intent-based APIs. Now, developers can more easily create a new generation of network-aware applications, and partners can integrate the network into business processes.

Streamline IT processes across functions: DNA Center helps enable network IT administrators to exchange information to automate processes across IT systems through software adapters. Now, IT can move resources from operation to innovation.

Managing multi-vendor networks: DNA Center gives developers and partners the flexibility to support multi-vendor networks via a software developer kit (SDK). This allows customers to simplify the complexity of heterogeneous networks and manage them consistently, as a single system. 

Already, 15 Cisco partners have built innovative solutions on the DNA Center platform and are demonstrating them at Cisco Live. 

Announcing the largest developer community for intent-based networking 
Cisco is also announcing that its developer community, DevNet, has surpassed 500,000 members. In building this large and active community, Cisco has introduced a new source of innovation as the network becomes increasingly programmable.

Today, Cisco is announcing three new developer initiatives to fuel its innovation ecosystem:

  • DevNet Ecosystem Exchange makes it easy to find and share an application or solution built for Cisco platforms. Business leaders and developers alike can use this online portal to discover partner solutions that span all Cisco platforms and products. It contains over 1,300 solutions.

  • DevNet Code Exchange gives developers a place to access and share software to quickly build next-generation applications and workflow integrations. A curated list of sample code, adaptors, tools, and SDKs is available on GitHub and written by Cisco and the DevNet community. Code Exchange spans Cisco's entire portfolio and is organized according to Cisco platform and product areas.

  • DevNet DNA Developer Center is a one-stop-shop for developers to build applications and integrations on the DNA Center platform. It provides comprehensive resources, capabilities, use cases and learning materials for developers.

Availability, Services and Support

  • The new DNA Center capabilities are scheduled to be available during the summer of 2018. Customers can purchase these new capabilities from Cisco and its partners via existing subscription offers.

  • DevNet's Ecosystem Exchange, Code Exchange, and DNA Developer Center are available now.

  • Cisco and its partners offer a full lifecycle of services to help customers streamline the journey to truly intent-based networks.

Additional Information

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco, the Cisco logo, Cisco and Cisco IOS Systems are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

Press Relations: 
Gareth Pettigrew
+1-250-240-0638
gpettigr@cisco.com

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum